Page last updated: 2024-12-05

4-toluic acid

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

4-toluic acid, also known as p-toluic acid, is a white crystalline organic compound with the formula CH3C6H4COOH. It is a derivative of benzoic acid, with a methyl group substituted at the para position. 4-toluic acid is commonly synthesized through oxidation of p-xylene or by the reaction of toluene with carbon monoxide and water in the presence of a catalyst. This compound is used in the production of dyes, pharmaceuticals, and other organic chemicals. It is also a precursor for the synthesis of various other compounds, including 4-toluenesulfonyl chloride, which is a key reagent in organic synthesis. 4-toluic acid exhibits weak acidic properties and is relatively stable under normal conditions. Its applications in chemistry and industry make it an important and widely studied compound.'
```

4-toluic acid: RN given refers to parent cpd; structure [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

p-toluic acid : A methylbenzoic acid in which the methyl substituent is located at position 4. [Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Cross-References

ID SourceID
PubMed CID7470
CHEMBL ID21708
CHEBI ID36635
SCHEMBL ID93638
MeSH IDM0054283

Synonyms (81)

Synonym
AC-3061
para-toluic acid
CHEBI:36635 ,
p-carboxytoluene
4-toluic acid
wln: qvr d1
p-methylbenzoic acid
p-toluylic acid
nsc-2215
benzoic acid, 4-methyl-
nsc2215
NCIOPEN2_001271
einecs 202-803-3
ai3-15627
nsc 2215
brn 0507600
AB-131/40170882
inchi=1/c8h8o2/c1-6-2-4-7(5-3-6)8(9)10/h2-5h,1h3,(h,9,10
NCGC00091128-01
99-94-5
toluenecarboxylic acid
4-methylbenzoic acid
p-toluic acid
toluate
crithminic acid
C01454
p-toluic acid, 98%
4ma ,
STK498227
4-methyl-benzoic acid
CHEMBL21708
BMSE000414
FT-0654542
T0293
AKOS000119644
A846107
NCGC00091128-02
dtxsid6021618 ,
cas-99-94-5
dtxcid801618
tox21_201091
NCGC00258643-01
a26gbx5ssv ,
unii-a26gbx5ssv
SCHEMBL93638
toluic acid, p-
p-toluic acid [mi]
4-methylbenzic acid
p-toluicacid
4-methyl benzoic acid
4-methylbenzenecarboxylic acid
rho-toluic acid
para toluic acid
diethylethylchloromalonate
W-100006
BS-3777
1219798-71-6
p-toluic-2,3,5,6-d4 acid
p-tolylcarboxylic acid
sampl4, o2
F1679-0157
CS-D0602
mfcd00002565
p-toluic acid, analytical standard
D70680
bdbm197303
p-toluic acid, vetec(tm) reagent grade, 98%
Z57902424
4-methylbenzoicacid
benzoic acid,4-methyl-
crithmic acid
2420-97-5 (cadmium salt)
SY003713
p-methyl benzoic acid
supported benzoic acid (100-200/2.5-3.0)
HY-76547
Q1607905
AM10618
EN300-18325
4-methylbenzoic acid4-methylbenzoic acid
4-methylbenzoic acid(flakes or chunks or granular)
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Drug Classes (1)

ClassDescription
methylbenzoic acid
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Protein Targets (6)

Potency Measurements

ProteinTaxonomyMeasurementAverage (µ)Min (ref.)Avg (ref.)Max (ref.)Bioassay(s)
aldehyde dehydrogenase 1 family, member A1Homo sapiens (human)Potency25.11890.011212.4002100.0000AID1030
glucocorticoid receptor [Homo sapiens]Homo sapiens (human)Potency1.12050.000214.376460.0339AID720691
nuclear factor erythroid 2-related factor 2 isoform 1Homo sapiens (human)Potency21.13170.000627.21521,122.0200AID651741
survival motor neuron protein isoform dHomo sapiens (human)Potency0.10000.125912.234435.4813AID1458
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Inhibition Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Sigma intracellular receptor 2Homo sapiens (human)Ki10.00000.00010.83604.6005AID1655661
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Biological Processes (10)

Processvia Protein(s)Taxonomy
nucleobase-containing compound metabolic processThiopurine S-methyltransferaseHomo sapiens (human)
xenobiotic metabolic processThiopurine S-methyltransferaseHomo sapiens (human)
methylationThiopurine S-methyltransferaseHomo sapiens (human)
xenobiotic catabolic processThiopurine S-methyltransferaseHomo sapiens (human)
regulation of cell growthSigma intracellular receptor 2Homo sapiens (human)
regulation of intracellular lipid transportSigma intracellular receptor 2Homo sapiens (human)
regulation of intracellular cholesterol transportSigma intracellular receptor 2Homo sapiens (human)
cholesterol homeostasisSigma intracellular receptor 2Homo sapiens (human)
positive regulation of wound healingSigma intracellular receptor 2Homo sapiens (human)
positive regulation of lipoprotein transportSigma intracellular receptor 2Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Molecular Functions (5)

Processvia Protein(s)Taxonomy
protein bindingThiopurine S-methyltransferaseHomo sapiens (human)
thiopurine S-methyltransferase activityThiopurine S-methyltransferaseHomo sapiens (human)
S-adenosyl-L-methionine bindingThiopurine S-methyltransferaseHomo sapiens (human)
protein bindingSigma intracellular receptor 2Homo sapiens (human)
oxysterol bindingSigma intracellular receptor 2Homo sapiens (human)
cholesterol bindingSigma intracellular receptor 2Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Ceullar Components (7)

Processvia Protein(s)Taxonomy
cytosolThiopurine S-methyltransferaseHomo sapiens (human)
endoplasmic reticulumSigma intracellular receptor 2Homo sapiens (human)
lysosomeSigma intracellular receptor 2Homo sapiens (human)
endoplasmic reticulumSigma intracellular receptor 2Homo sapiens (human)
rough endoplasmic reticulumSigma intracellular receptor 2Homo sapiens (human)
plasma membraneSigma intracellular receptor 2Homo sapiens (human)
rough endoplasmic reticulum membraneSigma intracellular receptor 2Homo sapiens (human)
nuclear membraneSigma intracellular receptor 2Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Bioassays (26)

Assay IDTitleYearJournalArticle
AID1060463Inhibition of Sir2p in yeast DMY2844 assessed as growth inhibition after 48 hrs2014Bioorganic & medicinal chemistry letters, Jan-01, Volume: 24, Issue:1
Evaluation of benzoic acid derivatives as sirtuin inhibitors.
AID1145614Dissociation constant, pKa of the compound1977Journal of medicinal chemistry, Jan, Volume: 20, Issue:1
Use of distribution coefficients in quantitative structure-activity relationships.
AID28692Concentration of the drug in the kidney of rat1992Journal of medicinal chemistry, Sep-04, Volume: 35, Issue:18
Energy aspects of oil/water partition leading to the novel hydrophobic parameters for the analysis of quantitative structure-activity relationships.
AID1145605Octanol-water partition coefficient, log P of the compound1977Journal of medicinal chemistry, Jan, Volume: 20, Issue:1
Use of distribution coefficients in quantitative structure-activity relationships.
AID1655667Displacement of [3H]-di-o-tolylguanidine from sigma2 receptor (unknown origin) at 10 uM incubated for 1 hr in presence of (+)SKF10047 by liquid scintillation counting method relative to control
AID125426Compound was tested for toxicity, calculated from isotoxic concentrations of substituted benzoic acids for 50% mortality of mosquito1983Journal of medicinal chemistry, Sep, Volume: 26, Issue:9
Ion-sensitive electrode potentiometry of organic anions: application to quantitative structure-activity relationships.
AID226478Hammett constant was evaluated1996Journal of medicinal chemistry, May-24, Volume: 39, Issue:11
Comparative molecular moment analysis (CoMMA): 3D-QSAR without molecular superposition.
AID1655668Cytotoxicity against human MCF7 cells assessed as reduction in cell viability at 100 uM after 24 hrs by MTT assay relative to control
AID631927Antihemorrhagic activity in ddY mouse assessed as inhibition of Protobothrops flavoviridis venom-induced hemorrhagic lesion formation compound incubated with venom for 10 mins and administered subcutaneously measured after 24 hrs2011Bioorganic & medicinal chemistry, Dec-01, Volume: 19, Issue:23
Benzenepolycarboxylic acids with potential anti-hemorrhagic properties and structure-activity relationships.
AID1655666Displacement of [3H]-(+)-pentazocine from sigma1 receptor in guinea pig brain membranes at 10 uM incubated for 1 hr by liquid scintillation counting method relative to control
AID28693Concentration of the drug in the liver of rat1992Journal of medicinal chemistry, Sep-04, Volume: 35, Issue:18
Energy aspects of oil/water partition leading to the novel hydrophobic parameters for the analysis of quantitative structure-activity relationships.
AID226477Hammett constant was determined1993Journal of medicinal chemistry, Oct-01, Volume: 36, Issue:20
QSAR's from similarity matrices. Technique validation and application in the comparison of different similarity evaluation methods.
AID1145615Dissociation constant, pKa of the compound at pH 7.81977Journal of medicinal chemistry, Jan, Volume: 20, Issue:1
Use of distribution coefficients in quantitative structure-activity relationships.
AID28731Partition coefficient (logD2.0)1992Journal of medicinal chemistry, Sep-04, Volume: 35, Issue:18
Energy aspects of oil/water partition leading to the novel hydrophobic parameters for the analysis of quantitative structure-activity relationships.
AID1145607Octanol-aqueous phase distribution coefficient, log D of the compound1977Journal of medicinal chemistry, Jan, Volume: 20, Issue:1
Use of distribution coefficients in quantitative structure-activity relationships.
AID28691log LD50 was determined1992Journal of medicinal chemistry, Sep-04, Volume: 35, Issue:18
Energy aspects of oil/water partition leading to the novel hydrophobic parameters for the analysis of quantitative structure-activity relationships.
AID631930Dissociation constant, pKa of the compound2011Bioorganic & medicinal chemistry, Dec-01, Volume: 19, Issue:23
Benzenepolycarboxylic acids with potential anti-hemorrhagic properties and structure-activity relationships.
AID1655660Displacement of [3H]-(+)-pentazocine from sigma1 receptor in guinea pig brain membranes incubated for 1 hr by liquid scintillation counting method
AID213093Inhibition of purified human kidney thiopurine methyltransferase (TPMT)1986Journal of medicinal chemistry, Mar, Volume: 29, Issue:3
Thiopurine methyltransferase: structure-activity relationships for benzoic acid inhibitors and thiophenol substrates.
AID1149945Inhibition of chymotrypsin (unknown origin)1977Journal of medicinal chemistry, Nov, Volume: 20, Issue:11
Quantitative structure-activity relationship of chymotrypsin-ligand interactions.
AID1145616Increase in membrane potential in mollusc neurons assessed as conductance of potassium at pH 7.8 relative to salicylic acid1977Journal of medicinal chemistry, Jan, Volume: 20, Issue:1
Use of distribution coefficients in quantitative structure-activity relationships.
AID1655661Displacement of [3H]-di-o-tolylguanidine from sigma2 receptor (unknown origin) incubated for 1 hr in presence of (+)SKF10047 by liquid scintillation counting method
AID29132pI50 was determined1992Journal of medicinal chemistry, Sep-04, Volume: 35, Issue:18
Energy aspects of oil/water partition leading to the novel hydrophobic parameters for the analysis of quantitative structure-activity relationships.
AID28497log (1/C') was determined1992Journal of medicinal chemistry, Sep-04, Volume: 35, Issue:18
Energy aspects of oil/water partition leading to the novel hydrophobic parameters for the analysis of quantitative structure-activity relationships.
AID1655663Cytotoxicity against human MCF7 cells assessed as reduction in cell viability after 24 hrs by MTT assay
AID1803087Urease Inhibition Assay from Article 10.3109/14756366.2011.599065: \\Synthesis, inhibitory activity and molecular docking studies of two Cu(II) complexes against Helicobacter pylori urease.\\2012Journal of enzyme inhibition and medicinal chemistry, Aug, Volume: 27, Issue:4
Synthesis, inhibitory activity and molecular docking studies of two Cu(II) complexes against Helicobacter pylori urease.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (60)

TimeframeStudies, This Drug (%)All Drugs %
pre-19909 (15.00)18.7374
1990's14 (23.33)18.2507
2000's13 (21.67)29.6817
2010's20 (33.33)24.3611
2020's4 (6.67)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 38.86

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be strong demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index38.86 (24.57)
Research Supply Index4.13 (2.92)
Research Growth Index4.77 (4.65)
Search Engine Demand Index53.50 (26.88)
Search Engine Supply Index2.00 (0.95)

This Compound (38.86)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Reviews1 (1.64%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other60 (98.36%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]